Table 2.

Questionnaire with number of respondents

	Yes	No	Not sure	Total
Have you heard of infliximab?	117 (77%)	28 (18%)	7 (5%)	152
Are you currently using infliximab?	42 (28%)	106 (70%)	4 (3%)	152
Have you used infliximab in the past?	60 (40%)	81 (53%)	11 (7%)	152
Have you ever had a discussion about the risks and benefits of infliximab with a health care provider?	76 (50%)	59 (40%)	17 (11%)	152
Patients’ estimates of the chance of remission from infliximab after 2 weeks	figure 1			137
Patients’ estimates of the chance of remission from infliximab after 1 year	figure 2			138
Patients’ estimates of the risk of lymphoma associated with infliximab compared to the general population	figure 3			135
Patients’ estimates of the risk of dying from a serious side effect of infliximab as compared to the general population	figure 4			138
Patients’ minimal demanded benefit of a drug with a death rate of 1/250	figure 5			146